Time filter

Source Type

Kitakyūshū, Japan

Laimer K.,Innsbruck Medical University | Troester B.,Tyrolean Cancer Research Institute | Troester B.,Innsbruck Medical University | Kloss F.,Innsbruck Medical University | And 11 more authors.
Oral Oncology | Year: 2011

Indoleamine 2,3 dioxygenase (IDO) is a negative immune regulator and was found to be a prognostic marker in several tumor entities. In this study, we analysed IDO expression in oral squamous cell carcinoma (OSCC) regarding patient's prognosis. Additionally, expression of IDO like-1 gene (INDOL-1) was analysed. Tumor tissue from 88 patients with OSCC was analysed by immunohistochemistry for IDO expression. The influence of IDO expression on survival was studied by multivariate Cox regression, adjusting for established clinical prognostic parameters. Real time PCR of tumor samples was performed in a subgroup of patients to analyse mRNA expression of IDO and INDOL-1. IDO high-expression was observed in 44.2% of OSCC patients. No significant correlation was found between IDO expression and clinical stage, sex, age, tumor site, tumor size, metastasis or tumor grade. The median overall survival time was 3.1 years for patients with IDO low tumors, compared to 1.36 years for IDO high tumors (P = .028). Subset analysis of patients receiving adjuvant radio-chemotherapy showed a significant difference (P = .0046) in overall survival between IDO low tumors (3.35 years) and IDO high tumors (1.26 years). In contrast, the impact of IDO expression on survival time in patients without adjuvant therapy was not significant (P = .574). Interestingly, INDOL-1 was not expressed in OSCC. IDO high expression represents a significant negative prognostic factor in patients with OSCC, especially in those patients undergoing adjuvant radiochemotherapy. Our data support the suggestion, co-administration of small-molecule IDO inhibitors could represent a promising new strategy to increase the anti-tumor activity of radio-chemotherapy in patients with IDO positive OSCC. © 2011 Elsevier Ltd. All rights reserved. Source

Nabee Z.,University of Mauritius | Allybucus N.,Pathological Laboratory | Jhugroo V.,Jawarlall Nehru Hospital | Kotea N.,University of Mauritius
Biomedicine (India) | Year: 2014

Introduction: Recent advances in biomedical technology, coupled with the lack of suitable reference counts for proper diagnosis, have necessitated the establishment of hematological reference values for white cells and platelet parameters of healthy full term newborns in Mauritius. Aim: The aim of the study was to determine the white cells and platelet parameters in umbilical cord blood of full term neonates, to establish a reference range for these indices and assess its validity. Materials and Methods: 150 full term, healthy newborns were included in the study according to defined inclusion and exclusion criteria for both neonates and mothers. Cord blood sampling was done upon delivery by caesarean section or vaginal route. White cells and platelet parameters were determined accordingly, using the Cell Dyne 3700 analyser. Data analysis was done using Statistical Package for Social Sciences (SPSS Version 16.0). Results: Mean white cell count and platelet count were found to be 11.88×10 9/L and 261×109/L respectively, which are lower than the standard values described in literature. One-sample t-tests for indices under this study revealed significant values p<0.05. Hypothesis testing confirmed that the mean indices in use cannot be blown on the population mean. Conclusion: This study provides suitable reference ranges in respect of the neonatal population and further recommends the phasing out of the actual reference ranges in favor of those derived, to herald for safer paediatric diagnosis in our local set-up. Source

Kikuma K.,Fukuoka University | Watanabe J.,Pathological Laboratory | Oshiro Y.,Pathological Laboratory | Oshiro Y.,Red Cross | And 10 more authors.
Virchows Archiv | Year: 2012

Sixty-four cases of malignant lymphoma involving the liver were examined. Of these, 20 cases were histologically confirmed to be primary hepatic B-cell lymphoma. Twelve of these 20 cases were diffuse large B-cell lymphoma (DLBCL) and eight cases were mucosa-associated lymphoid tissue (MALT) lymphoma. Of the 12 cases of DLBCL, six were immunohistologically positive for CD10 and/or Bcl6 (indicating a germinal center phenotype), six were positive for Bcl2, and five were positive for CD25. Eight of the 12 DLBCL cases (66.7%) and two of the eight MALT lymphoma cases (25%) had serum anti-hepatitis C virus (HCV) antibodies and HCV RNA. The incidence of HCVinfection was significantly higher in the hepatic DLBCL cases than in systemic intravascular large B-cell cases with liver involvement (one of 11 cases, 9.1%) and T/NK-cell lymphoma cases (one of 19 cases, 5.3%) (p<0.01 for both). Two hepatic DLBCL cases (16.7%) had rheumatoid arthritis treated with methotrexate, and four MALT lymphoma cases (50%) had Sjögren's syndrome, primary biliary cirrhosis, or autoimmune hepatitis; one case in each of these two groups was complicated by chronic HCVseropositive hepatitis. Although primary hepatic lymphoma is rare, persistent inflammatory processes associated with HCV infection or autoimmune disease may play independent roles in the lymphomagenesis of hepatic B cells. © Springer-Verlag 2012. Source

Discover hidden collaborations